Revolution Medicines
PublicRevolution Medicines is now publicly traded
The data on this page reflects Revolution Medicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 18, 2020
Last Round
Convertible Debt
Apr 17, 2026
Total Funding Raised
$2.97B
Company Overview
Revolution Medicines operates in Biotech and is based in Redwood City, California. Its recorded funding history includes a Series C round in July 2019.
Revolution Medicines is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers.
Sector
Biotech
AI Layer
Infrastructure
Revolution Medicines Comparables
Compare Revolution Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SciBrunch Therapeutics | 65% | |
| Haptena Therapeutics | 64% | |
| Machavert Pharmaceuticals | 62% |
For institutional investors. Book with your work email.
Revolution Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Apr 17, 2026 | ||||
| Follow-on Offering | Apr 17, 2026 | ||||
| Corporate Funding | Jun 24, 2025 | ||||
| IPO | Feb 18, 2020 | ||||
| Series C | Jul 9, 2019 | ||||
Series B | Apr 24, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Revolution Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series C, Series A Extension, Series B |
| Deerfield Management | Series C |
| Boxer Capital | Series C |
| Guggenheim Securities | IPO |
| Cormorant Asset Management | Series C |
| Fidelity Management & Research Company | Series C |
| Royalty Pharma | Corporate Funding |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueNov 5, 2026
Revolution Medicines, Inc. reports $198M in Q3 '26 sales from its KRAS inhibitor Rasonque after five weeks of availability.
- receives_awardOct 30, 2026
On Oct 30th '26 in China, Medicilon presents Revolution Medicines, Inc. with the Excellence in Client Partnership Award for the substantial clinical value of its pioneering pan-KRAS drug discovery and development.
- attends_eventOct 23, 2026
In 2026, Revolution Medicines, Inc. attends the ASCO congress, where its Rasonque causes a stir in pancreatic cancer.
- is_developingOct 16, 2026
Revolution Medicines, Inc. is developing zoldonrasib as a monotherapy and in combination with Rasonque.
- is_developingOct 14, 2026
On Oct 14th '26, Revolution Medicines, Inc. is developing zoldonrasib specifically to target G12D.
For institutional investors. Book with your work email.
Revolution Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.